BORIS and CTCF are overexpressed in squamous intraepithelial lesions and cervical cancer

Abstract

ABSTRACT. We investigated the expression of Brother of Regulator of Imprinted Sites (BORIS) and CCCTC-binding factor (CTCF) in squamous intraepithelial lesions and cervical cancer. To analyze BORIS and CTCF expression, an endocervical cytobrush sample was taken for total RNA isolation. CTCF and BORIS mRNA was quantified from total RNA using quantitative reverse transcription-polymerase chain reaction. A total of 71 samples were collected and classified according to the Bethesda Classification of squamous intraepithelial lesions. BORIS 6095 BORIS and CTCF expression in cervical dysplasia and cancer ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (2): 6094-6100 (2015) expression was observed in 9 (12.7%) samples; of these, 5.3, 5.9, 14.8, and 37.5% in the groups that were cytology negative for intraepithelial lesion or malignancy, low-grade squamous intraepithelial lesions (LSIL), highgrade squamous intraepithelial lesions (HSIL), and invasive cervical carcinoma, respectively. The expression level of BORIS was significantly higher in the group with invasive cervical carcinoma as compared with the groups negative for intraepithelial lesion or malignancy, LSIL, and HSIL (P < 0.0005). CTCF mRNA was expressed in all samples. CTCF expression was significantly higher in carcinoma groups compared with LSIL, HSIL, and negative for intraepithelial lesion or malignancy groups. We found that BORIS and CTCF expressions in the LSIL and invasive cervical carcinoma groups were higher than expression in cytological normal samples. Additional studies should be conducted to examine the function of transcription factors during different stages of the transformation of cervical cancer cells.

Zinc Finger Protein CTCF Regulates Extracellular Matrix (ECM)-Related Gene Expression Associated With the Wnt Signaling Pathway in Gastric Cancer

“…Its expression pattern and roles in different tumor types vary greatly. For instance, CTCF overexpression was previously reported in breast cancer ( 11 ), cervical cancer ( 12 ), ovarian cancer ( 13 ), and hepatocellular carcinoma ( 14 ) and is often related to tumor features with adverse prognostic impacts. Additionally, mutations in CTCF or defects in CTCF function have been observed in GC ( 16 ).…”

“…CTCF, a well-known transcription factor that is essential in organizing chromatin into highly self-interacting, topologically associated domains, has recently become of great interest to researchers in the cancer field ( 10 ). CTCF overexpression has been identified in breast cancer ( 11 ), cervical cancer ( 12 ), ovarian cancer ( 13 ), and hepatocellular carcinoma ( 14 ). Some mutations are related to tumors ( 15 ).…”

BORIS: a key regulator of cancer stemness

“…For instance, Vatolin et al and Hong et al demonstrated that the suppressed expression of BORIS (observed in normal somatic tissues and cell lines), is abrogated in various breast, neuroblastoma, prostate, melanoma, colon, and lung cancers [ 11 ]. In other studies, the comparative expression analysis of several cancer/testis genes revealed a high incidence of BORIS expression in uterine/endometrial, ovarian and cervical cancers in comparison with their normal tissues [ 17 , 24 , 32 , 56 ]. In similar reports, analysis of BORIS in esophageal squamous cancers, pancreatic and hepatocellular carcinoma indicated that the expression of BORIS was significantly higher in these cancers than that in the adjacent non-cancerous tissues and normal cells [ 46 , 47 , 49 , 57 ].…”

Expression of CCCTC‐binding factor (CTCF) is linked to poor prognosis in prostate cancer

“…Similar findings have been reported from other solid cancer types. For example, CTCF was more strongly expressed in breast and cervical cancers as compared to very low CTCF levels detected in normal breast tissues and in low-grade intraepithelial lesions of the cervix (Docquier et al, 2005;Velazquez-Hernandez et al, 2015).…”